BridgeMD
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD )
EU CTIS ID: 2025-523283-21-00
What this study is testing
To demonstrate that orforglipron is superior to placebo in increasing maximum walking distance.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have symptoms of Peripheral Artery Disease (PAD), causing pain when you walk
You likely can't join if
- Have a BMI less than 23 kg/m2
- Have HbA1c greater than 10%
- Have had or plan to have a leg surgery to improve blood flow in your legs
- Have had a heart condition within 60 days prior to screening
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Australia
- Korea, Republic of
- Taiwan
- Brazil
- China
- Japan
- Argentina
- India
- United Kingdom
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Australia; Korea, Republic of; Taiwan; Brazil; China and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.